🧠 Food for thought

Implications, context, and why it matters.

Yosemite’s new fund target and AUM claim should be verified against public disclosures

• The investment mandate for Yosemite’s new fund targeting $350 million should be spelled out, including its target stage, average check size, and deployment cadence.
• These inputs are needed for assessing the firm’s operating discipline.
• The reported assets under management figure of more than $1 billion, including assets it handles for endowments, hospitals and foundations, should be checked against public regulatory filings or other authoritative disclosures to confirm the venture firm’s scale 1.

Yosemite’s radiopharma ambitions could increase demand for isotope supply and CDMO capacity

• Yosemite plans to incubate radiopharmaceutical companies, which develop targeted radioactive drugs, and that could tighten demand for specialized infrastructure.
• Therapeutic isotopes such as actinium-225 or lutetium-177 may face greater supply pressure. NorthStar Medical Radioisotopes, LLC and Nusano have described efforts to expand production and commercial availability of these isotopes 23.
• Some development work may move to specialized contract development and manufacturing organizations (CDMOs), outsourced partners that help biotech companies develop or manufacture drugs. Custom Market Insights projects this market will rise from $3.1 billion in 2025 to $7.2 billion by 2034, which equals a 9.3% CAGR from 2025 to 2034 4.
• Backers could fund enabling services, build tooling, or team up with providers that can serve Yosemite’s future portfolio companies.